| FibroGen, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120039882 | Vascular Disease Therapies - The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided. | 02-16-2012 |
| 20110305776 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS - The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). | 12-15-2011 |
| 20110263644 | Compounds and Methods for Treatment of Stroke - The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke. | 10-27-2011 |
| 20110263642 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS - The present invention relates to methods and compounds useful for treating multiple sclerosis. | 10-27-2011 |
| 20110207671 | METHOD FOR PRODUCING DOUBLE-CROSSLINKED COLLAGEN - The present invention relates to double-crosslinked collagen materials, methods for preparing double-crosslinked collagen materials, and methods of using double-crosslinked | 08-25-2011 |
| 20110166178 | Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase - The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds. | 07-07-2011 |
| 20110166145 | Stabilization of hypoxia inducible factor (HIF) alpha - The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided. | 07-07-2011 |
| 20110091468 | Connective tissue growth factor antibodies - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 04-21-2011 |
| 20110039885 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS - The present invention relates to methods and compounds useful for increasing endothelial progenitor cell levels in blood and bone marrow. Methods and compounds for increasing endothelial progenitor cell mobilization are also provided. | 02-17-2011 |
| 20110039879 | METHODS FOR INCREASING WHITE BLOOD CELLS - The present invention relates to methods and compounds useful for increasing white blood cell levels in blood and bone marrow. Methods and compounds for increasing hematopoietic progenitor cells are also provided. | 02-17-2011 |
| 20110015223 | Compounds and methods for treatment of cancer-related anemia - The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are refractory to treatment with recombinant human erythropoietin (EPO) are encompassed herein. | 01-20-2011 |
| 20100331362 | Treatment method for anemia - The present invention relates to improved methods for treating anemia. Methods and compounds useful for treating anemia, wherein the anemia treatment is associated with a lower risk of thrombosis or hypertension compared to that observed with rhEPO therapy, are provided. | 12-30-2010 |
| 20100303928 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS - The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme. | 12-02-2010 |
| 20100291098 | Diabetic nephropathy therapies - The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided. | 11-18-2010 |
| 20100204269 | Compounds and methods for treatment of chemotherapy-induced anemia - The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein. | 08-12-2010 |
| 20100168152 | Fat regulation - The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e.g., obesity, diabetes, atherosclerosis, etc. | 07-01-2010 |
| 20100144737 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION - The present invention relates to methods and compounds useful for inhibiting T helper cell differentiation. Methods and compounds for decreasing IL-12 signaling in T helper cells are also provided. | 06-10-2010 |
| 20090325302 | Diagnostic marker for diabetic vascular complications - The present invention relates to the discovery that CTGF is a diagnostic marker indicative of increased risk for development and progression of vascular disease. | 12-31-2009 |
| 20090143568 | Recombinant gelatins - The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same. | 06-04-2009 |
| 20090017559 | Methods for diagnosing renal disorders - The present invention relates to methods for diagnosing the presence and progress of pathologies characterized by an accumulation of the extracellular matrix components by measuring the level of Connective Tissue Growth Factor (CTGF) in a sample. The method of the present invention is directed to diagnosing kidney fibrosis and associated renal disorders, in particular, complications associated with diabetes, hyperglycemia, and hypertension. | 01-15-2009 |
| 20090017043 | Connective tissues growth factor antibodies - The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney. | 01-15-2009 |
| 20080254487 | Connective Tissue Growth Factor Signaling - The present invention provides compounds and agents that modulate CTGF-mediated cell adhesion and/or binding of CTGF to cells. The invention further provides assays that may be used to identify additional modulators of CTGF-mediated cell adhesion and CTGF binding to cells, and assays that may be used to identify compounds or agents that modulate interaction of CTGF with HSPGs. | 10-16-2008 |
| 20080206256 | Treatments for cancer - The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents. | 08-28-2008 |
